CD8A and neoplasm: Preclinical and clinical studies demonstrated that gemcitabine treatment reduced the amount of MDSCs (30, 33) and increased the cytotoxicity of anti-tumor CD8+ T cells and NK cells (32), this may contribute to enhanced responses to CAR-T cells.